Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. Fischer, B. Fischer, S. Tzotzos, H. Pietschmann, R. Lucas (Vienna, Austria; Augusta, United States Of America). Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients. Eur Respir J 2011; 38: Suppl. 55, 3503

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Impacts of inhaled corticosteroids on antiviral and antibacterial immunity in the lung Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection Year: 2019 Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Morphological evidence of anti-inflammatory effect of interferon-α at pulmonary TB patients Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 An influence of small doses of corticosteroids on immune defense in active pulmonary tuberculosis in humans Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Inflammatory phenotypes of asthma determine effect of inhaled corticosteroids on anti-viral immunity Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Antituberculous activity of fiurenizid in vitro and in patients with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis Source: Eur Respir J 2012; 40: 271-273 Year: 2012 Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007